DEBATES

DEBATES
DEBATE 1
Motion: Neuropathic pain questionnaires are suitable for NP classification
Chair: Audun Stubhaug, Oslo University Hospital, Norway
For the motion: Rainer Freynhagen, Germany
Against the motion: Per Hansson, Oslo University Hospital, Norway
DEBATE 2
Motion: The culprit for chronic neuropathic pain is in the central nervous
system
Chair: Matthias Ringkamp, Johns Hopkins University, USA
For the motion: Anthony Dickenson, University College London, UK
Against the motion: Jordi Serra, Barcelona, Spain
DEBATE 3
Motion: Opioids have no place in the management of neuropathic pain
Chair: Andrew Moore, UK
For the motion: Cathy Stannard, Pain Clinic, Macmillan Centre, Frenchay Hospital,
Bristol, UK.
Against the motion: Elon Eisenberg, Haifa, Israel
DEBATE 4
Motion: Fibromyalgia is primarily a centralized pain amplification disorder
Chair: Serge Perrot, CHU Hôtel Dieu, Paris, France
For the motion: To be announced
Against the motion: Claudia Sommer, Wurzburg, Germany
WORKSHOPS OVERVIEW
5/ CLINICAL ASSESSMENT OF NEUROPATHIC PAIN: FROM QUESTIONNAIRES
TO QUATITATIVE SENSORY (not in parallel with the others)
Chair : Per Hansson, Norway
Detection of neuropathic pain: how to use the screening tools?
Michel Lanteri-Minet, Nice, France
Clinical sensory examination
Per Hansson, Oslo University Hospital, Norway
QST: general principles and practical applications
Helena Krumova, Germany
6/ PAIN IN CNS DISORDERS – ARE WE MOVING FORWARD?
Chair: Troels J. Jensen, Denmark
Pain in Parkinson’s Disease: time to move forward
Daniel Ciampi de Andrade, University of Sao Paulo, Brazil
Post-Stroke Pain
Luis Garcia-Larrea, Inserm U1028, Lyon, France
Pain in multiple sclerosis and other inflammatory demyelinating diseases
Andrea Truini, Sapienza University, Rome, Italy
7/ UPDATE ON NEUROPATHIC PAIN AND INFECTIOUS DISEASES
Chair: Aki Hietaharju, Finland
Neuropathic pain in leprosy
Andrew Rice, Imperial College, London, UK
HIV-associated sensory neuropathy
Peter Kamerman, University of the Witwatersrand, South Africa
Postherpetic Neuralgia
Ralf Baron, Christian-Albrechts-Universität Kiel, Germany
8/ RISK FACTORS AND PREVENTION OF POSTSURGICAL NP
Chair: Audun Stubhaug, Oslo University Hospital, Norway
Neuropathic aspects of persistent postsurgical pain: state of the art
Christian Duale, CHU Clermont-Ferrand, France
Psychological and somatic risk factors for neuropathic postsurgical pain
Julie Bruce Warwick Clinical Trials Unit, University of Warwick, UK
Perioperative interventions: how to individualize treatments
Audun Stubhaug, Oslo University Hospital, Norway
9/ NEUROPATHIC AND PERSISTENT IDIOPATHIC FACIAL PAIN: MECHANISMS
AND MANAGEMENT
Chair: Barry Sessle, University of Toronto, Canada
Extraterritorial behavioral hypersensitivity and dorsal horn central
sensitization in trigeminal neuropathic pain models : role of glial and genetic
factors
Barry Sessle, University of Toronto, Canada
Neuron-glial interactions contribute to extraterritorial spread in trigeminal
neuropathic pain
Koichi Iwata, Nihon University, Japan
Assessment and management of orofacial neuropathic and idiopathic facial
pain in humans
Peter Svensson, Aarhus University, Denmark
10/ SMALL FIBERS, LARGE EFFECTS – A NW ROLE IN FIBROMYALGIA
SYNDROME?
Chair: Nurcan Üçeyler, Wurzburg, Germany
Fibromyalgia: to be or not to be... neuropathic?
Serge Perrot, Hotel Dieu hospital, Paris
Small fiber pathology in patients with fibromyalgia syndrome
Anne Louise Oaklander, Harvard, USA
Abnormalities in peripheral C-nociceptors of patients with fibromyalgia
syndrome.
Jordi Serra, MC Mutual, Barcelona, Spain
11/ NEUROPATHIC ITCH
Chair: Allan Basbaum, USA
Neuropathic itch: an overview
Earl Carstens, University of California, USA
Presentation title to be announced
Matthias Ringkamp, USA
Presentation title to be announced
Rolf-Detlef Treede, Germany
12/ CHEMOTHERAPY – INDUCED PAINFUL NEUROPATHY: LATEST
PERSPECTIVES
Chair: Sarah Flatters, King's College London, UK
Mitochondrial dysfunction and oxidative stress in Chemotherapy-induced
painful neuropathy
Sarah Flatters, King's College London, UK
Targeting sphingosine-1-phosphate in Chemotherapy-Induced Peripheral
Neuropathy
Daniela Salvemini, Saint Louis University School of Medicine, USA
New psychophysical and functional findings in chemotherapy-treated patients
Patrick Dougherty, University of Texas M.D. Anderson Cancer Center, USA
13/ THE (UN) DOUBTFUL NEP COMPONENT IN « NONNEUROPATIC» PAIN
DISORDERS
Chair: Ralf Baron, Germany
Insights from questionnaires
Didier Bouhassira, INSERM, France
Insights from quantitative sensory testing
Joanna Höper, Kiel, Germany
Insights from brain imaging
Thomas Tölle, Germany
14/ CONFOCAL CORNEAL MICROSCOPY (CCM) – A NEW DIAGNOSTIC TOOL
FOR NEUROPATHY OR THE NEXT «HYPE»?
Chair: Christoph Maier, Bergmannsheil University Hospital Bochum, Germany
An overview of CCM methodology
Rayaz Malik, Division of Cardiovascular Medicine, University of Manchester,
Manchester, UK
Reliability and diagnostic pitfalls of CCM
Tunde Peto, Moorfields Eye Hospital NHS Foundation Trust and UCL Institute of
Ophthalmology, UK
CCM, skin punch biopsy and QST- comparison of the diagnostic validity in
neuropathic pain
Maier Christoph, Hospital Bochum, Germany
15/ RELEVANCE OF NEUROPHYSIOLOGIC TESTS FOR THE STUDY OF
PAINFUL NEUROPATHIES: AN UPDATE
Chair: Rolf-Detlef, Treede, Germany
Contact heat, cold, mechanical, electrical and chemical stimuli to elicit small
fiber potentials: merits and limitations for basic science and clinical use
Rolf Treede, Detlef, Mannheim, Germany
The relevance of LEPs in patients with suspected neuropathic pain
Luis Garcia-Larrea, Hôpital Neurologique, Inserm, Lyon, France
Autonomic tests for the study of painful neuropathies: where do we stand?
Roy Freeman, Harvard, USA
16/ Phenotyping neuropathic pain for genetic and clinical studies: from mice to
men
Chair: Peter Kamerman, University of the Witwatersrand, South Africa
Phenotyping for genetic studies in animal models of neuropathic pain
Zeev Seltzer, Canada
NeuroPPIC: Neuropathic pain phenotyping by international consensus?
Peter Kamerman, University of the Witwatersrand, South Africa
Phenotyping in clinical trials of neuropathic pain
Didier Bouhassira, INSERM, France
17/ THERAPEUTIC MANAGEMENT OF NEUROPATHIC PAIN: NEWER NEUPSIG
RECOMMENDATIONS T
Chair: Nanna Finnerup, Aarhus University, Denmark
Presentation of the NEUPSIG methodology
Nadine Attal, INSERM U 987 and APHP, Boulogne, France
NEUPSIG recommendations on drug treatment of neuropathic pain
Nanna Finnerup, Aarhus University, Denmark
NEUPSIG recommandations on interventional therapy for neuropathic pain
Srinivasa Raja, John Hopkins University, USA
18/ CENTRAL NERVOUS SYSTEM STIMULATION FOR NEUROPATHIC PAIN:
THE EVIDENCE.
Chair: Luis Garcia-Larrea, INSERM, Lyon, France
Evidence-based studies in neurostimulation:a difficult task but we are moving
forward
Giorgio Cruccu, University la Sapienza, Roma, Italy
Evidence-based efficacy of spinal cord stimulation in neuropatic pain
Rod Taylor, University of Exeter Medical School, UK
Motor cortex stimulation in neuropathic pain: from anecdote to evidence
Luis Garcia-Larrea, Lyon Centre for Neuroscience, France
19/ OPTIONS FOR PHARMACORESISTANT PATIENTS WITH TRIGEMINAL
NEURALGIA
Chair: Giorgio Cruccu, Sapienza University, Roma, Italy
The problem of pharmacoresistance in trigeminal neuralgia
Giorgio Cruccu, Sapienza University, Roma, Italy
Alternative options for pharmacoresistant patients
Turo Nurmikko, University of Liverpool, UK
How to choose the type of surgical intervention
Denis Fontaine, Hôpital Pasteur, Nice, France (neurosurgeon)
20/ DEVELOPING CLINICALLY USEFUL CANNABINOID RELATED
ANALGESICS FOR NEUROPATHIC PAIN
Chair: Rafael, Maldonado, Spain
Clinical limitations of conventional CB1 agonists
Turo Nurmikko, UK
FAAH inhibition: a new therapeutic target for neuropathic pain
Daniele Piomelli, Genoa, Italy
CB2 receptor agonists for the prevention of neuropathic pain development
Rafael Maldonado, Spain
21/ NEUROPATHIC PAIN – LESSONS TO BE LEARNED FROM CLINICAL AND
PRECLINICAL META ANALYSES
Chair Gilllian Currie, University of Edinburgh, UK
Challenges in pre-clinical meta-analyses of neuropathic pain, focus on animal
models
Gilllian Currie, University of Edinburgh, UK
Detecting publication bias and the impact on both preclinical and clinical
research
Emily Sena, Florey Institute of Neuroscience and Mental Health/University of
Edinburgh, UK
Challenges in clinical meta-analyses in neuropathic pain
Haroutiunian Simon, USA
22/ DO THE EYES HAVE IT? SPATIAL REPRESENTATIONS, MULTI SENSORY
INTERACTION AND VISUAL ILLUSIONS IN NEUROPATHIC PAIN
Chair: Tasha Stanton, University of South Australia, Australia
Targeting perceptual dysfunction in people with pain.
Tasha Stanton, University of South Australia, Australia
Can seeing your body help? The role of visual feedback in musculoskeletal
and neuropathic pain
Martin Diers, Heidelberg University, Germany
The influence of visuo-spatial processing on pain.
Diana Torta, Universite Catholique de Louvain, Belgium
23/ IS CRPS A NEGLECT-LIKE DISORDER?
Chair: Lorimer Moseley, University of South Australia, Australia
Spatially-defined deficits in CRPS
Lorimer, Moseley University of South Australia, Australia
Attending to and representing the body and the space around it.
Alberto Gallace, University of Milano-Bicocca, Italy
Disrupted body representation phenomena in CRPS
Annika Reinersmann, Universitätsklinikum Bergmannsheil, Bochum, Germany
24/ BRAIN IMAGING IN NEUROPATHIC PAIN: ROLE IN ASSESSING
MECHANISMS AND TREATMENT EFFECTS
Chair: Karen Davis, Toronto Western Research Institute, Canada
Brain imaging of treatment effects in chronic pain conditions
Karen Davis, Toronto Western Research Institute, Canada
Brain network properties predict individual variability in analgesia related to
psychological aspects of treatment in chronic pain patients
Javeria Hashmi, Harvard Medical School and Massachusetts General Hospital, USA
The maladaptive neuroplasticity theory - 20 years on
Martin Diers, Heidelberg University, Germany
25/ THE ENIGMA OF PAIN AND AFFECTIVE DISORDERS COMORBIDITY IN
ANIMAL MODELS AND PATIENTS WITH NEUROPATHIC PAIN
Chair: Esther Berrocoso, University of Cadiz, Spain
Neuroplastic changes triggered by the comorbidity of neuropathic pain and
affective disorders
Esther Berrocoso, University of Cadiz, Spain
The anterior cingulate cortex: a critical hub for the anxiodepressive
consequences of neuropathic pain
Ipek Yalcin, Institut des Neurosciences Cellulaires et Intégratives, France
A strong association between cognitive function, anxiety and mood and the
development of chronic neuropathic pain in humans
Sophie Baudic, INSERM U 987, Hospital Ambroise Pare, Boulogne, France
26/ AFFECTIVE AND COGNITIVE PAIN MODULATION IN NEUROPATHIC PAIN
Chair: Mark Jensen, USA
Thalamic dysregulation and neuropathic pain
Sylvia Gustin, Australia
Expectation and pain relief: impact on brain activity
Christian Büchel, Hamburg, Germany
Modulation therapy of neuropathic pain (hypnosis, meditation, mindfulness):
state of the art
Mark Jensen, USA
27/ EXPERIMENTAL DESIGN, CONDUCT AND REPORTING OF IN VIVO
NEUROPATHIC PAIN MODELLING: WORKING TOWARDS SUCCESFUL
TRANSLATION
Chair: Andrew Rice, Imperial College London, UK
Multi-centre animal studies- the way forward for translational research?
Andrew Rice, Imperial College London, UK
Back to basics- the importance of pharmacology in the design and conduct of
experiments
Jeffrey Kennedy, Eli Lilly and Company, USA
Experimental design, conduct and reporting in studies of animal models of
neuropathic pain
Gilllian Currie, University of Edinburgh, UK
28/ SYSTEM BIOLOGY IN NEUROPATHIC PAIN – NEW APPROACH, NEW
MECHANISTIC INSIGHT
Chair: Tim Hucho, University of Cologne, Germany
Analysis of intracellular signaling networks indicates novel therapeutic
strategies
Tim Hucho, University of Cologne, Germany
Insights into neuropathic pain provided by transcriptome analysis
David Bennett, University of Oxford, UK
Evolutionary genome analysis reveals novel pain genes and therapeutic
targets
Greg Neely, Garvan Institute, Australia
29/ SELECTIVE SMALL MOLECULE ANGIOTENSIN II TYPE 2 RECEPTOR
(AT2R) ANTAGONIST AS POTENTIAL NOVEL ANALGESICS FOR RELIEF OF
NEUROPATHIC AND INFLAMMATORY PAIN
Chair: Maree Smith, The University of Queensland, Australia
Analgesic Efficacy and Mode of Action of Small Molecule AT2R Antagonists in
Rodent Models of Neuropathic and Inflammatory Pain
Maree Smith, The University of Queensland, Australia
Clinical Mechanism of Action of AT2R Antagonists in Chronic Neuropathic
Pain
Praveen Anand, Imperial College London, UK
Clinical Evaluation of AT2R Antagonists for Neuropathic Pain
Andrew Rice, Imperial College London, UK
30/ PERIPHERAL SODIUM AND CALCIUM CHANNELS AS OPPORTUNE
TARGETS FOR NEUROPATHIC PAIN TREATMENT
Chair: Dib-Hajj Sulayman, Yale sch Med/VACT Healthcare System, USA
Mutations in peripheral sodium channels Nav1.7, Nav1.8 and Nav1.9 in rare
pain disorders and common peripheral neuropathy.
Dib-Hajj Sulayman, Yale, USA
The contribution of specific sodium channels to pain signaling pathways
John Wood, UCL, London, UK
Involvement of calcium channels in pathophysiology of neuropathic pain:
electrophysiological and behavioral evidences
Emmanuel Bourinet, CNRS, Montpellier, France
31/ POTASSIUM CHANNELS IN NEUROPATHIC PAIN : ADVANCES,
CHALLENGES AND EMERGING IDEAS
Chair: Alain Eschalier, Clermont Ferrand, France
Emerging Kv targets for chronic pain pharmacotherapy
Christoforos Tsantoulas, University of Cambridge, UK
M-current modulation of pain processing
Jose Lopez-Garcia, Universidad de Alcalá, Spain
Pathophysiology and pharmacology of potassium channels in neuropathic
pain
Jérome Busserolles, Inserm/ University of Auvergne, France
32/ THE ROLE OF GLIA IN PAIN DISORDERS: FROM RODENTS TO HUMANS
Chair: Marco Loggia, Massachusetts General Hospital / Harvard Medical School,
USA
Astrocyte signaling in neuropathic pain
Yong-Jing Gao, Nantong University, China
Microglial-neuronal signalling in the maintenance of neuropathic pain
Marzia Malcangio, King's College London, UK
Evidence of glial activation in the brain of patients with chronic low back pain
Marco Loggia, Massachusetts General Hospital / Harvard Medical School, USA
33/ AUTO-IMMUNE PAIN – AN EMERGING CONCEPT
Chair: Steven McMahon, UK
The role of immune system in the generation of neuropathic pain
Steven McMahon, UK
Pain associated with autoantibodies
Angela Vincent, University of Oxford, UK
Immunoglobulin for the treatment of peripheral neuropathy and CRPS
Stefano Tamburin, University of Verona, Italy

Download Report